Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Gene|November 2, 2023
Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapyJanani Sambath, Vanita Noronha, Srikanth S Manda, et al.
Ecancermedicalscience|March 5, 2024
Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in IndiaVanita Noronha, Laboni Sarkar, Vijay Patil, et al.
Cancers|March 28, 2024
Deep-Learning-Based Predictive Imaging Biomarker Model for EGFR Mutation Status in Non-Small Cell Lung Cancer from CT ImagingAbhishek Mahajan, Vatsal Kania, Ujjwal Agarwal, et al.
Oncotarget|November 8, 2019
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancerVijay Patil, Amit Joshi, Vanita Noronha, et al.
Lung India : Official Organ of Indian Chest Society|January 11, 2018
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Amit Joshi, Vijay Patil, Vanita Noronha, et al.
Ecancermedicalscience|November 7, 2017
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapyVanita Noronha, Vijay Patil, Amit Joshi, et al.
Journal of Global Oncology|July 19, 2017
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung CancerVijaya Raj Bhatt, Sanyo P D'Souza, Lynette M Smith, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
JTO Clinical and Research Reports|November 30, 2023
Real-World Evidence of EGFR Targeted Therapy in NSCLC- A Brief Report of Decade Long Single Center ExperienceAnuradha Chougule, Pratik Chandrani, Vanita Noronha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2019
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung CancerVanita Noronha, Vijay Maruti Patil, Amit Joshi, et al.
Pageof 4